<DOC>
	<DOCNO>NCT02989129</DOCNO>
	<brief_summary>The goal clinical research study learn effectiveness quercetin treat prevent CINP . Researchers also want learn quercetin effect participant 's quality life .</brief_summary>
	<brief_title>Trial Quercetin Treatment Prevention Chemotherapy-induced Neuropathic Pain Cancer Patients</brief_title>
	<detailed_description>Study Product Administration : If participant find eligible take part study , participant take quercetin tablet mouth 2 time every day 12 week . The study staff give participant tablet additional instruction take study product . Length Participation : Participant may take quercetin 12 week . Participant longer able take quercetin pain symptom get bad , intolerable side effect occur , participant unable follow study direction . Study Visits : Every week , participant either come clinic member staff call participant learn participant , participant side effect , check participant take quercetin correctly . Participant also complete questionnaire pain symptom participant may . The call/questionnaire take 10-15 minute complete . End-of-Study Visit : About 7 day participant 's last dose quercetin , participant complete questionnaire participant complete screening . Participation study end-of-study visit . This investigational study . Quercetin commercially available supplement , FDA approved.The study doctor explain study product design work . Up 20 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Quercetin</mesh_term>
	<criteria>1 . Patients &gt; 18 year old . 2 . Patients start , undergo complete chemotherapy MD Anderson Cancer Center 3 . Any cancer patient receive chemotherapeutic agent list developed neuropathic pain treatment cohort ; cancer patient schedule receive chemotherapeutic agent list preventive cohort . The chemotherapeutic agent include 1 ) taxanes ( paclitaxel , docetaxel ) , 2 ) vinca alkaloid ( vincristine , vinblastine ) , 3 ) platinum agent ( cisplatin , carboplatin , oxaliplatin ) , 4 ) others ( thalidomide , bortezomib , lenalidomide ) . 4 . Patients neuropathic pain intensity least 4/10 numeric rating score ( NRS , 0/10 pain 10/10 excruciate pain ) treatment cohort ; 0/10 NRS preventive cohort . 5 . Patients stable dose medication 6 . Patients follow Pain Medicine department . Patients normal renal function ( Normal value , BUN ( blood urea nitrogen ) : 8 20 mg/dL , Creatinine : 0.7 1.3 mg/dL ) . 7 . Patients able speak English . 8 . Patients able review , understand , provide write consent . 9 . Patients Eastern Cooperative Oncology performance ( ECOG ) status 02 . 1 . Renal impairment . 2 . Pregnancy . 3 . Hypersensitivity reaction , anaphylaxis , serious adverse reaction quercetin product component . 4 . Patients enrol another Pain Medicine trial . 5 . Patients malabsorption syndrome resection stomach small bowel . 6 . Patients condition precludes use study medication determine treat physician . 7 . Patients take Quercetin medical reason . 8 . Patients take Digoxin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Polyneuropathies Other Disorders Peripheral Nervous System</keyword>
	<keyword>Chemotherapy Induced Neuropathic Pain</keyword>
	<keyword>CINP</keyword>
	<keyword>Quercetin</keyword>
	<keyword>Questionnaires</keyword>
	<keyword>Surveys</keyword>
</DOC>